LexAurum Advisors LLC Has $763,000 Stake in Eli Lilly and Company (NYSE:LLY)

24 Dec 2023, 16:06 by Danessa Lincoln · The Markets Daily

LexAurum Advisors LLC trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 32.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,420 shares of the company’s stock after selling 674 shares during the period. LexAurum Advisors LLC’s holdings in Eli Lilly and Company were worth $763,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Retirement Group LLC increased its stake in Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after buying an additional 35 shares during the last quarter. Cornerstone Planning Group LLC acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at $33,000. Raleigh Capital Management Inc. increased its stake in Eli Lilly and Company by 156.4% in the 1st quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock valued at $34,000 after buying an additional 61 shares during the last quarter. Activest Wealth Management acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at $40,000. Finally, RVW Wealth LLC acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at $46,000. 81.38% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 215,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 11th. The shares were sold at an average price of $605.44, for a total value of $130,169,600.00. Following the completion of the transaction, the insider now directly owns 99,768,810 shares in the company, valued at approximately $60,404,028,326.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CAO Donald A. Zakrowski sold 670 shares of Eli Lilly and Company stock in a transaction on Monday, November 6th. The shares were sold at an average price of $571.10, for a total transaction of $382,637.00. Following the completion of the transaction, the chief accounting officer now owns 4,708 shares of the company’s stock, valued at $2,688,738.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of Eli Lilly and Company stock in a transaction on Wednesday, October 11th. The stock was sold at an average price of $605.44, for a total transaction of $130,169,600.00. Following the transaction, the insider now directly owns 99,768,810 shares of the company’s stock, valued at approximately $60,404,028,326.40. The disclosure for this sale can be found here. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Eli Lilly and Company in a research note on Thursday, November 9th. They set a “hold” rating and a $535.00 price objective on the stock. Argus boosted their price objective on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a research note on Tuesday, September 5th. Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $727.00 to $822.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 18th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $583.24.

Read Our Latest Report on LLY

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $570.39 on Friday. The company has a 50 day moving average of $587.53 and a 200-day moving average of $536.24. Eli Lilly and Company has a 1-year low of $309.20 and a 1-year high of $629.97. The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 1.59. The company has a market cap of $541.48 billion, a PE ratio of 103.33, a price-to-earnings-growth ratio of 3.48 and a beta of 0.33.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, November 2nd. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.18. The business had revenue of $9.50 billion during the quarter, compared to analysts’ expectations of $8.88 billion. Eli Lilly and Company had a net margin of 15.55% and a return on equity of 48.12%. As a group, equities research analysts forecast that Eli Lilly and Company will post 6.6 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 4th. Shareholders of record on Thursday, February 15th will be given a $1.30 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.13. This represents a $5.20 annualized dividend and a yield of 0.91%. The ex-dividend date is Wednesday, February 14th. Eli Lilly and Company’s dividend payout ratio is 81.88%.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).